Incyte (INCY)
NASDAQ:INCY
Want to see INCY full AI Analyst Report?
INCY Stock Chart & Stats
$97.82
$0.53(0.72%)
At close: 4:00 PM EST
$97.82
$0.53(0.72%)
Day’s Range― - ―
52-Week Range$66.74 - $112.29
Previous CloseN/A
Volume384.35K
Average Volume (3M)1.46M
Market Cap
$19.57B
Enterprise Value$15.90B
Total Cash (Recent Filing)$4.02B
Total Debt (Recent Filing)$33.83M
Price to Earnings (P/E)14.1
Beta0.51
Next Earnings
Aug 04, 2026EPS Estimate
1.78Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)7.30
Shares Outstanding199,782,150
10 Day Avg. Volume1,490,314
30 Day Avg. Volume1,455,767
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)3.73
Price to Sales (P/S)3.75
P/FCF Ratio14.23
Enterprise Value/Market Cap0.81
Enterprise Value/Revenue2.97
Enterprise Value/Gross Profit3.21
Enterprise Value/Ebitda8.50
Forecast
1Y Price Target
$108.80Price Target Upside11.22% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering18
EPS Forecast (FY)7.53
Revenue Forecast (FY)$5.62B
Bulls Say, Bears Say
Bulls Say
Low Leverage / Strong Balance SheetExtremely low debt-to-equity (~0.01) provides durable financial flexibility to fund late-stage trials, multiple launches, and potential M&A without stressing liquidity. This structural strength reduces bankruptcy risk and supports multi-year R&D investment and commercial scale-up even if revenues fluctuate.
Robust Cash Generation & High MarginsStrong trailing-twelve-month operating and free cash flow, and very high gross margins (~92%), create persistent internal funding for pipeline and launches. High cash conversion (FCF ≈ net income) sustains capital allocation flexibility and reduces reliance on external financing across a 2–6 month horizon and longer.
Late-stage Pipeline And Launch ReadinessA concentrated set of late-stage catalysts and planned launches (Jakafi XR, Opzelura EU, povorcitinib, Monjuvi) materially diversifies future revenue streams. Combined with leadership hires and an integrated commercial organization, this structural pipeline progress can change the company’s revenue mix and reduce single-product reliance over coming years.
Bears Say
Revenue Concentration In JakafiA substantial portion of sales remains tied to Jakafi, leaving the company exposed to clinical, competitive, labeling or payor changes. Durable growth requires successful launches (XR, Opzelura, new approvals); any execution miss or market pressure on Jakafi would have outsized impact on cash flow and strategic plans.
Elevated R&D And Operating SpendSustained, sizable R&D and SG&A guidance implies heavy ongoing investment to drive late-stage programs and launches. While necessary for growth, this structural spend elevates execution risk and could strain near-term profitability and cash if programs are delayed or fail, increasing sensitivity to trial outcomes.
Regulatory / Manufacturing Execution RiskA CRL tied to a third‑party fill‑finish facility delays label expansion and monetization of Zynyz in NSCLC. Reliance on external manufacturers introduces durable execution risk: remediation and resubmission timelines can be lengthy and affect revenue ramp assumptions while requiring regulatory coordination and potential additional costs.
Incyte News
INCY FAQ
What was Incyte’s price range in the past 12 months?
Incyte lowest stock price was $66.74 and its highest was $112.29 in the past 12 months.
What is Incyte’s market cap?
Incyte’s market cap is $19.57B.
When is Incyte’s upcoming earnings report date?
Incyte’s upcoming earnings report date is Aug 04, 2026 which is in 59 days.
How were Incyte’s earnings last quarter?
Incyte released its earnings results on Apr 28, 2026. The company reported $1.81 earnings per share for the quarter, beating the consensus estimate of $1.339 by $0.471.
Is Incyte overvalued?
According to Wall Street analysts Incyte’s price is currently Undervalued.
Does Incyte pay dividends?
Incyte does not currently pay dividends.
What is Incyte’s EPS estimate?
Incyte’s EPS estimate is 1.78.
How many shares outstanding does Incyte have?
Incyte has 199,782,150 shares outstanding.
What happened to Incyte’s price movement after its last earnings report?
Incyte reported an EPS of $1.81 in its last earnings report, beating expectations of $1.339. Following the earnings report the stock price went up 2.116%.
Which hedge fund is a major shareholder of Incyte?
Currently, no hedge funds are holding shares in INCY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Incyte Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$108.80 (11.22% Upside)
$108.80 (11.22% Upside)
Blogger Sentiment
Bullish
INCY Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 1.3M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $5.2M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.7%
Last 30 Days ▼ 2.2%
Last 30 Days ▼ 2.2%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
52.26%
12-Months-Change
Fundamentals
Return on Equity
29.31%
Trailing 12-Months
Asset Growth
27.65%
Trailing 12-Months
Company Description
Incyte
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include ruxolitinib, a steroid-refractory chronic graft-versus-host-diseases (GVHD); itacitinib, which is in Phase II/III clinical trial to treat naive chronic GVHD; and pemigatinib for treating bladder cancer, cholangiocarcinoma, myeloproliferative syndrome, and tumor agnostic. In addition, the company engages in developing Parsaclisib, which is in Phase II clinical trial for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma. Additionally, it develops Retifanlimab that is in Phase II clinical trials for MSI-high endometrial cancer, merkel cell carcinoma, and anal cancer, as well as in Phase II clinical trials for patients with non-small cell lung cancer. It has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Calithera Biosciences, Inc; MacroGenics, Inc.; Merus N.V.; Syros Pharmaceuticals, Inc.; Innovent Biologics, Inc.; Zai Lab Limited; Cellenkos, Inc.; and Nimble Therapeutics, as well as clinical collaborations with MorphoSys AG and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was incorporated in 1991 and is headquartered in Wilmington, Delaware.
INCY Company Deck
INCY Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented strong commercial momentum and substantial pipeline/regulatory progress: double‑digit top‑line growth (Q1 revenue +21%, net sales +20%), outsized core ex‑Jakafi growth (+63% YoY), multiple late‑stage programs and regulatory acceptances (povorcitinib, 989 EOP meeting, 734 Phase III) and leadership hires to support launches. Offsetting risks include elevated R&D/operating spend, a small safety review and administrative hold related to pneumonitis in the 734 program, and continued revenue concentration in Jakafi. On balance the positives—robust revenue growth, core business acceleration, and clear late‑stage catalysts—outweigh the lowlights, though execution and safety monitoring remain important near‑term considerations.View all INCY earnings summariesINCY Revenue Breakdown
84.69% Product revenues, net
12.39% Product royalty revenues
2.92% Milestone and contract revenues
INCY Stock 12 Month Forecast
Average Price Target
$108.80
▲(11.22% Upside)
Technical Analysis
Ownership Overview
15.20% Insiders
23.18% Mutual Funds
18.20% Other Institutional Investors
15.16% Public Companies and Individual Investors